当前位置:首页 >财报库 > 中译版报告详情

嘉德诺Cardinal Health(CAH)2023财年第三季度财报(中译版)(15页).pdf

上传人: Kell****reet 编号:134428 2023-07-28 15页 917.56KB

下载:

1、Exhibit 99.1 FOR IMMEDIATE RELEASE Cardinal Health Reports Third Quarter Fiscal Year 2023 Results and Raises Fiscal Year 2023 Non-GAAP EPS Guidance Revenue increased 13%to$50.5 billion GAAP1 operating earnings were$572 million;GAAP diluted EPS was$1.34 Non-GAAP operating earnings increased 11%to$606

2、 million;non-GAAP diluted EPS increased 20%to$1.74 Fiscal year 2023 non-GAAP EPS guidance raised and narrowed to$5.60 to$5.80,from$5.20 to$5.50 Fiscal year 2023 adjusted free cash flow guidance raised and narrowed to$2.0 to$2.3 billion,from$1.5 to$2.0 billion DUBLIN,Ohio,May 4,2023 Cardinal Health(N

3、YSE:CAH)today reported third quarter fiscal year 2023 revenues of$50.5 billion,an increase of 13%from the third quarter of fiscal year 2022.Third quarter GAAP operating earnings were$572 million and GAAP diluted earnings per share(EPS)were$1.34.Third quarter non-GAAP operating earnings increased 11%

4、to$606 million due to a significant increase in Pharmaceutical segment profit,partially offset by a decline in Medical segment profit.Non-GAAP diluted EPS increased 20%to$1.74,reflecting the improvement in non-GAAP operating earnings,a lower share count and lower interest expense,partially offset by

5、 a higher non-GAAP effective tax rate.Our third quarter results were led by continued momentum and growth in the Pharmaceutical segment,”said Jason Hollar,CEO of Cardinal Health.With the strong overall performance in the quarter,we are pleased to raise our full year non-GAAP EPS guidance by$0.35 at

6、the midpoint.In Medical,we continue to see improvement in underlying performance and remain confident in our Medical Improvement Plan initiatives.Across the enterprise,we continue to operate with urgency to drive our businesses forward and create value for our shareholders.Q3 FY23 summary Q3 FY23 Q3

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
Cardinal Health发布了2023财年第三季度财报,总收入增长13%至505亿美元,其中制药部门收入增长14%至468亿美元,医疗部门收入下降5%至37亿美元。GAAP净利润为3.45亿美元,每股摊薄后盈利1.34美元;非GAAP净利润为4.47亿美元,每股摊薄后盈利1.74美元。公司提高了2023财年非GAAP每股盈利预期至5.60至5.80美元,并提高了调整后自由现金流预期至20至23亿美元。
凯德莱健康第三季度的收入增长了多少? 凯德莱健康第三季度的非GAAP每股收益是多少? 凯德莱健康提高了2023财年的非GAAP每股收益预期吗?
客服
商务合作
小程序
服务号
折叠